In this online, self-learning activity:
IBD is a broad term that includes many different forms of inflammatory bowel conditions, the most common of which are ulcerative colitis (UC) and Crohn’s disease, the former of which exclusively affects the colon and rectum. Guidelines exist for the treatment of UC, but they are constantly changing to include updated information. Despite the plethora of guidelines available, there are issues surrounding guideline adherence by physicians, patient satisfaction, the quality of treatment and a patient’s QOL. Given the data from multiple studies that physicians are either not aware of updated practice guidelines or are not utilizing them, that this lack of knowledge is affecting patient satisfaction, and that there may be demographically-based barriers to care, educational activities are warranted to keep HCPs abreast of best practices in patients with UC. This activity has been designed to review treatment strategies, emerging therapies, and gaps in care of patients with UC.
This activity is a learning activity focused on Ulcerative Colitis and its complications, designed to bring healthcare providers up to date in their practice and give them a sense of coming changes to practice and the literature.
Healthcare professionals specializing in: gastroenterology, internal medicine, and those who otherwise commonly care for patients with UC.
This activity is supported by an educational grant from Salix / Bausch Health.
Learners may participate in this activity free of charge.
Release Date: September 23, 2019 -- Expiration Date: September 23, 2021
Faculty: Berkeley Limketkai, M.D., Ph.D.
Faculty member introduction, disclosures, overview of Ulcerative Colitis
Major findings from DDW 2019, including clinical trial data relevant to both community and health-system practice and recognized barriers to implementing those findings in practice (specific content contingent upon conference content)
Predicted of applicability to clinical practice and patient cases, where relevant
By the end of the session the participant will be able to:
As a provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review ScientiaCME.
Faculty Disclosure: Berkeley N. Limketkai, M.D., Ph.D. , has no relevant financial disclosures.
Disclosures of Educational Planners: Charles Turck, PharmD, BCPS, BCCCP, President of ScientiaCME, has no relevant financial disclosures.
*Required to view Printable PDF Version
Please take a few minutes to participate in the optional pre-test. It will help us measure the knowledge gained by participating in this activity.
Ulcerative Colitis (UC): Optimizing Pharmacotherapeutic Management Strategies
Pediatric Crohn's disease: Therapeutic updates and optimizing treatment
Employing biosimilars in the treatment of inflammatory health conditions: How to and should I?
Short bowel syndrome: therapeutic updates and optimizing treatment